The European Medicines Agency (EMA) has also granted accelerated assessment for the Marketing Authorisation Application (MAA) for Kymriah as a treatment for children and young adults with r/r B-cell
acute lymphoblastic leukaemia (ALL) and for adult patients with r/r DLBCL who are ineligible for ASCT.
In addition, the European Medicines Agency (EMA) has granted accelerated assessment to the Marketing Authorization Application (MAA) for Kymriah for the treatment of children and young adults with r/r B-cell
acute lymphoblastic leukemia (ALL) and for adult patients with r/r DLBCL who are ineligible for ASCT.
The new B-Cell
and 5Unbiased Enrichment Kits will add to the Chromium V(D)J Solution for Immune Repertoire Sequencing, first launched for paired T-Cell receptor sequencing last spring.
lymphomas are small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL).
Keywords: T-cell/histiocyte-rich large B-cell
lymphoma; diffuse large B-cell
lymphoma; gastric malignancies.
GlobalData epidemiologists forecast an increase in the incident cases of the four B-cell
NHL in the 7MM, from 104,854 incident cases in 2014 to 129,179 incident cases in 2024, with an annual growth rate (AGR) of 2.
This immune surveillance accounts for what researchers at the institute call the 'surprising rarity' of B-cell
lymphomas in the population, given how often these spontaneous changes occur.
With approval by the Italian Medicines Agency (AIFA), the company's medicinal product PIXUVRI (pixantrone) will use used as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell
non-Hodgkin lymphoma (patients with aggressive B-cell
NHL who failed two or three prior lines of therapy).
Primary cutaneous large B-cell
lymphomas (leg type) (PCBLS) are diffuse large cell B-cell
lymphomas with predominance or confluent sheets of centroblasts and immunoblasts.
has initiated a phase II clinical trial of SGN-40 for the treatment of patients with diffuse large B-cell
lymphoma, the most common type of aggressive non-Hodgkin's lymphoma (NHL).
LONDON -- Borrelia burgdorferi from tick bites, the causative agent of Lyme disease in the United States, has been linked to cases of primary cutaneous B-cell
lymphoma in certain areas of Europe, reported Rein Willemze, M.
ZEVALIN is approved in Europe for the treatment of adult patients with CD20+ follicular B-cell
non-Hodgkin's lymphoma (NHL) who are refractory to or have relapsed following RITUXAN (rituximab) therapy.
The proposed examples include B-cell
epitopes specific-to Leishmania identified by a number of laboratories working with visceral Leishmania spp.
Treatment of the lymph node cancer called diffuse large B-cell
lymphoma is all-or-nothing.
This report provides information on the therapeutic development for B-Cell
Chronic Lymphocytic Leukemia, complete with latest updates, and special features on late-stage and discontinued projects.